207 related articles for article (PubMed ID: 35482409)
21. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
[TBL] [Abstract][Full Text] [Related]
22. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A (
Karamafrooz A; Brennan J; Thomas DD; Parker LL
J Proteome Res; 2021 Oct; 20(10):4815-4830. PubMed ID: 34436901
[TBL] [Abstract][Full Text] [Related]
23. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
24. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1).
Zhu Q; Gong L; Wang J; Tu Q; Yao L; Zhang JR; Han XJ; Zhu SJ; Wang SM; Li YH; Zhang W
BMC Cancer; 2016 Oct; 16(1):806. PubMed ID: 27756250
[TBL] [Abstract][Full Text] [Related]
25. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract][Full Text] [Related]
26. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract][Full Text] [Related]
27. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
Rüland L; Andreatta F; Massalini S; Chuva de Sousa Lopes S; Clevers H; Hendriks D; Artegiani B
Nat Commun; 2023 May; 14(1):2377. PubMed ID: 37137901
[TBL] [Abstract][Full Text] [Related]
28. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
[TBL] [Abstract][Full Text] [Related]
29. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IκB.
Fang L; Sun J; Pan Z; Song Y; Zhong L; Zhang Y; Liu Y; Zheng X; Huang P
Am J Physiol Gastrointest Liver Physiol; 2017 Aug; 313(2):G150-G156. PubMed ID: 28526689
[TBL] [Abstract][Full Text] [Related]
31. Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma.
Wojcicka A; Swierniak M; Kornasiewicz O; Gierlikowski W; Maciag M; Kolanowska M; Kotlarek M; Gornicka B; Koperski L; Niewinski G; Krawczyk M; Jazdzewski K
Int J Biochem Cell Biol; 2014 Aug; 53():208-17. PubMed ID: 24875649
[TBL] [Abstract][Full Text] [Related]
32. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma.
Sun XF; Sun JP; Hou HT; Li K; Liu X; Ge QX
Tumour Biol; 2016 Nov; 37(11):15325-15332. PubMed ID: 27704356
[TBL] [Abstract][Full Text] [Related]
34. The Use of Fluorescence
Weiel JJ; Forgo B; Sage J; Rangaswami A; Hazard FK
Ann Clin Lab Sci; 2022 May; 52(3):475-483. PubMed ID: 35777788
[TBL] [Abstract][Full Text] [Related]
35. DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma.
de Oliveira S; Houseright RA; Korte BG; Huttenlocher A
Dis Model Mech; 2020 Apr; 13(4):. PubMed ID: 32102783
[TBL] [Abstract][Full Text] [Related]
36. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
Lalazar G; Simon SM
Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
[TBL] [Abstract][Full Text] [Related]
37. microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit.
Shi X; Liu TT; Yu XN; Balakrishnan A; Zhu HR; Guo HY; Zhang GC; Bilegsaikhan E; Sun JL; Song GQ; Weng SQ; Dong L; Ott M; Zhu JM; Shen XZ
Oncogene; 2020 Aug; 39(35):5768-5781. PubMed ID: 32719439
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
[TBL] [Abstract][Full Text] [Related]
39. The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.
Reid LM; Sethupathy P
Hepatology; 2016 Feb; 63(2):662-4. PubMed ID: 26505878
[No Abstract] [Full Text] [Related]
40. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]